EXTH-23. BICISTRONIC CAR-T CELLS TARGETING EGFR AND IL13RΑ2 MITIGATE ANTIGENIC HETEROGENEITY IN GLIOMA

抗原 嵌合抗原受体 胶质瘤 下调和上调 癌症研究 体内 生物 肿瘤抗原 体外 表皮生长因子受体 受体 免疫疗法 免疫学 免疫系统 基因 遗传学
作者
Nannan Li,Yibo Yin,Jesse L. Rodriguez,Meghan Logun,Logan Zhan,Jiasi Zhang,Zev A. Binder,Zhiguo Lin
出处
期刊:Neuro-oncology [Oxford University Press]
卷期号:24 (Supplement_7): vii214-vii214
标识
DOI:10.1093/neuonc/noac209.822
摘要

Abstract Chimeric antigen receptor (CAR)-T cells have had a significant effect in hematological diseases, with a recent study confirming that the cells can last for ten years in vivo. Unfortunately, to date, CAR-T cells have had little effect in solid tumors. One cause of the treatment difficulty is antigenic heterogeneity. Our experience with CAR-T cells in glioblastoma suggests that addressing antigenic heterogeneity may improve the clinical efficacy. Targeting the epidermal growth factor receptor (EGFR) and interleukin 13 receptor subunit alpha 2 (IL13Rα2) individually could lead to tumor control in the short term, but it will be marked by tumor recurrence through antigen loss or downregulation in the long term. This resistance mechanism can be inhibited by combinatorial targeting. To this end, we have designed a bicistronic construct that targets both EGFR and IL13Rα2 simultaneously, to decrease the potential of antigen escape and tumor recurrence. The bicistronic CAR-T cells employ an “OR” logic gate to modify the T cells and kill the tumor cells in vitro and in vivo, in order to retain effectiveness when one target antigen is lost but the second is still present. Our experimental results demonstrate that and validate the safety and possibility of clinical translation. In addition, the efficiency of transfecting T cells with the single bicistronic vector was higher than two single vectors on monovalent CARs. In summary, the bicistronic CAR-T structure is a promising strategy to address the clinical problem of targeting antigenic heterogeneity in solid tumors and potentially level the barriers for targeted T-cell therapy. Educational Objectives: After completion, participants will be able to explain the importance of antigenic heterogeneity in solid tumors in the context of tumor escape. Participants will also be able to identify a strategy to reducing the problem of antigen escape and tumor recurrence through the implementation of bicistronic CARs.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
科研小虫完成签到,获得积分10
1秒前
mingxuan完成签到,获得积分10
1秒前
Tashanzhishi发布了新的文献求助10
2秒前
怕孤单的寒天完成签到,获得积分10
2秒前
邱燈发布了新的文献求助10
2秒前
hhh完成签到,获得积分10
2秒前
缥缈月光完成签到,获得积分10
2秒前
mmmm完成签到,获得积分10
2秒前
memedaaaah完成签到,获得积分10
3秒前
snowman完成签到,获得积分10
3秒前
3秒前
快乐小狗发布了新的文献求助10
3秒前
科研通AI2S应助沉默的婴采纳,获得10
3秒前
LiLi完成签到,获得积分10
3秒前
Nora完成签到,获得积分10
3秒前
小嘀嗒完成签到,获得积分10
4秒前
Wenllly完成签到,获得积分10
4秒前
chiweiyoung完成签到,获得积分10
4秒前
乐观海燕发布了新的文献求助10
4秒前
min20210429发布了新的文献求助10
5秒前
5秒前
刘佳玮完成签到,获得积分10
5秒前
不舍天真完成签到,获得积分10
6秒前
有机菜花完成签到,获得积分20
6秒前
宫冷雁完成签到,获得积分10
6秒前
华仔应助Sky采纳,获得10
6秒前
ZZ完成签到,获得积分10
7秒前
Mandy完成签到,获得积分10
7秒前
7秒前
7秒前
科研通AI6.4应助陌上花开采纳,获得10
7秒前
CodeCraft应助niuma采纳,获得10
7秒前
LIN_YX发布了新的文献求助10
7秒前
九妹完成签到,获得积分10
7秒前
megan发布了新的文献求助10
7秒前
DuanJN完成签到,获得积分10
8秒前
赵小胖完成签到 ,获得积分10
8秒前
菲菲菲菲完成签到,获得积分20
8秒前
cd发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea de Guyane Insecta, Polyneoptera 2000
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
Signals, Systems, and Signal Processing 610
Research Methods for Business: A Skill Building Approach, 9th Edition 500
Research Methods for Applied Linguistics 500
Picture Books with Same-sex Parented Families Unintentional Censorship 444
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6414089
求助须知:如何正确求助?哪些是违规求助? 8232863
关于积分的说明 17478627
捐赠科研通 5466990
什么是DOI,文献DOI怎么找? 2888549
邀请新用户注册赠送积分活动 1865542
关于科研通互助平台的介绍 1703257